Pfizer: A Defensive Play For ObamaCare Ruling

In a year that is set to feature a battle for the White House, it is somewhat hard to believe that an equally important battle is already underway. As the U.S. Supreme Court remains on the brink of ruling on the Landmark ObamaCare case, weakness in the U.S. jobs report last week has reawakened the Federal Reserve’s fervor for printing money. By using the healthcare sector as a lens through which to observe this battle, one should be able to not only see the issues more clearly, but capitalize on this understanding toward the end of making profitable trading decisions.

ObamaCare

A ruling on President Obama’s Affordable Healthcare Act is expected to be handed down by the High Court sometime this month. This is a critical landmark decision because it will not only define how healthcare is purchased in the U.S. moving forward, but it may define the very nature of the role of government. For most, the core issue is whether or not the government is empowered to require its citizens to purchase something.

Without careful consideration, one may conclude that the government is already in the business of requiring to citizens to buy things – we all pay taxes and pay the fee to have a driver’s license and license plates. In those cases, however, those costs are predicated on some action by the individual or on some privilege being conferred. In other words, those costs may be avoided.To continue reading, click here.